natgillin/translations-raw huggingface dataset:
Empirical Therapy in Febrile, Neutropaenic Adult Patients: A total of 1,111 patients with persistent fever and neutropaenia were enrolled in a clinical study and treated with either caspofungin 50 mg once daily following a 70 mg loading dose or liposomal amphotericin B 3.0 mg/kg/day. 
Empirično zdravljenje febrilnih, nevtropeničnih odraslih bolnikov: Klinična študija je zajela skupno 1.111 bolnikov s trdovratno zvišano telesno temperaturo in nevtropenijo.
• Chills, fever 
• mrzlica, zvišana telesna temperatura
Class 
Višina
Preparation of the 50 mg/m infusion for paediatric patients >3 months of age (using a 70-mg vial) Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient's BSA (as calculated above) and the following equation: BSA (m2) X 50 mg/m2 = Daily Maintenance Dose 
Priprava infuzije 50 mg/m za pediatrične bolnike, stare >3 mesece (z uporabo viale po 70 mg) Dejanski dnevni vzdrževalni odmerek za pediatričnega bolnika določite na podlagi njegove telesne površine (izračunane, kot je prikazano zgoraj) po naslednji enačbi: Telesna površina (m2) X 50 mg/m2 = dnevni vzdrževalni odmerek
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
Sočasna uporaba z induktorji presnovnih encimov
• Inflammation of the vein 
• zvišana telesna temperatura
50 mg / 100 mg 
50 mg/100 mg filmsko obložena tableta peroralna uporaba pretisni omot (alu/alu)
Oral use blister (alu/alu) 
Pot uporabe Stična ovojnina Velikost pakiranja
Pack size 
Zepatier
It is available as capsules (100 and 400 mg) and tablets (100 and 400 mg) and is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut. 
Na voljo je v obliki kapsul (100 in 400 mg) in tablet (100 in 400 mg) in se jemlje peroralno ob obroku z velikim kozarcem vode za zmanjšanje draženja želodca in črevesja.
What measures are being taken to ensure the safe and effective use of Imatinib Teva? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Imatinib Teva?
The European Commission granted a marketing authorisation valid throughout the European Union for Imatinib Teva on 8 January 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Imatinib Teva, veljavno po vsej Evropski uniji, izdala 8. januarja 2013.
It is also used in adults and children in the ‘chronic phase' of the disease if it is not responding to interferon alpha (another cancer medicine), and in more advanced phases of the disease (‘accelerated phase' and ‘blast crisis'); 
Uporablja se tudi pri odraslih in otrocih v kronični fazi bolezni, če se ta ne odziva na interferon alfa (drugo zdravilo za zdravljenje raka), ter v napredovalih fazah bolezni (pospešeni fazi in blastni krizi);
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imatinib Teva have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
These enzymes can be found in certain receptors in cancer cells, including the receptors that are involved in stimulating the cells to divide uncontrollably. 
Ti encimi se nahajajo v določenih receptorjih v rakavih celicah, vključno z receptorji, ki spodbujajo celice, da se nenadzorovano delijo.
The dose depends on the age and condition of the patient, and the response to treatment, but it should not exceed 800 mg a day. 
Odmerek je odvisen od starosti bolnika, njegovega bolezenskega stanja in odziva na zdravljenje, vendar ne sme presegati 800 mg na dan. Za več informacij glejte navodilo za uporabo.
This means that Imatinib Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Glivec. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Glivec.
This is a summary of the European public assessment report (EPAR) for Imatinib Teva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Imatinib Teva.
This means that it blocks some specific enzymes known as tyrosine kinases. 
To pomeni, da zavira delovanje določenih encimov, imenovanih tirozin kinaze.
It is also used alone in adults to treat Ph+ ALL that has returned following previous treatment, or is not responding to other medicines; 
Uporablja se tudi samostojno pri odraslih za zdravljenje Ph+ ALL, ki se je po predhodnih zdravljenjih ponovno pojavila ali se ne odziva na druga zdravljenja;
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Imatinib Teva has been shown to have comparable quality and to be bioequivalent to Glivec. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Imatinib Teva primerljivo raven kakovosti kot zdravilo Glivec ter da mu je biološko enakovredno.
Other information about Imatinib Teva 
Druge informacije o zdravilu Imatinib Teva
By blocking these receptors, Imatinib Teva helps to control cell division. 
Z zaviranjem teh receptorjev zdravilo Imatinib Teva pomaga pri nadzoru deljenja celic.
What are the benefits and risks of Imatinib Teva? 
Kakšne so koristi in tveganja, povezani z zdravilom Imatinib Teva?
Because Imatinib Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Imatinib Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
This means that some of their genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome. 
To pomeni, da so se nekateri geni prerazporedili in tvorijo poseben kromosom Philadephia.
The full EPAR for Imatinib Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Imatinib Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Imatinib Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Imatinib Teva is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body. 
Zdravilo Imatinib Teva se uporablja za zdravljenje odraslih z (DFSP), ki ga ni mogoče odstraniti s kirurškim posegom ter pri odraslih, ki niso primerni za kirurški poseg po ponovnem pojavu raka po zaključenem zdravljenju ali pri razširitvi na druge dele telesa.
Imatinib Teva is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; 
Zdravilo Imatinib Teva se uporablja za zdravljenje odraslih s HES ali CEL, ki imajo posebno preureditev dveh genov, imenovanih FIP1L1 in PDGFRα;
What is Imatinib Teva and what is it used for? 
Kaj je zdravilo Imatinib Teva in za kaj se uporablja?
For practical information about using Imatinib Teva, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Imatinib Teva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Because Imatinib Teva is a generic medicine, studies in patients have been limited to tests to determine that the tablets and capsules are bioequivalent to the reference medicine, Glivec. 
Ker je zdravilo Imatinib Teva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali so tablete in kapsule biološko enakovredne referenčnemu zdravilu Glivec.
Therefore, the CHMP's view was that, as for Glivec, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Glivec odtehtajo znana tveganja.
The active substance in Imatinib Teva, imatinib, is a protein-tyrosine kinase inhibitor. 
Zdravilna učinkovina v zdravilu Imatinib Teva, imatinib, je zaviralec beljakovine tirozin kinaze.
The Committee recommended that Imatinib Teva be given marketing authorisation. 
Priporočil je, da se za zdravilo Imatinib Teva izda dovoljenje za promet.
Imatinib Teva is used in combination with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL. 
Zdravilo Imatinib Teva se uporablja v kombinaciji z drugimi zdravili za zdravljenje raka pri odraslih in otrocih z novo ugotovljeno Ph+ ALL.
• myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells. 
• mielodisplastične ali mieloproliferativne bolezni (MDS/MPD), skupine bolezni, pri katerih telo proizvaja velike količine nenormalnih krvnih celic.
• dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably. 
• protuberantnega dermatofibrosarkoma (DFSP), vrste raka (sarkoma), pri kateri se celice pod kožo nenadzorovano delijo.
Imatinib Teva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood. 
Predpisovanje in izdaja zdravila Imatinib Teva je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem krvnega raka.
Imatinib Teva is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR); 
Zdravilo Imatinib Teva se uporablja za zdravljenje odraslih z MDS/MPD v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFRplatelet derived growth factor receptor);
• Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly. 
• Ph+ akutne limfoblastne levkemije (ALL), vrste raka, pri kateri se limfociti (druga vrsta belih krvnih celic) prehitro množijo.
Why is Imatinib Teva approved? 
Zakaj je bilo zdravilo Imatinib Teva odobreno?
Imatinib Teva is a cancer medicine. 
Zdravilo Imatinib Teva je zdravilo za zdravljenje raka.
Imatinib Teva is used when the patients are ‘Philadelphia chromosome positive' (Ph+). 
Zdravilo Imatinib Teva se uporablja pri bolnikih s prisotnim kromosomom Philadelphia (Ph+).
• advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control. 
• napredovalega hipereozinofilnega sindroma (HES) ali kronične eozinofilne levkemije (CEL), bolezni, pri katerih eozinofilci (druga vrsta belih krvnih celic) začnejo nenadzorovano rasti.
Imatinib Teva is used in adults and children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant. 
Zdravilo Imatinib Teva se uporablja pri odraslih in otrocih, pri katerih je bila Ph+ KML na novo ugotovljena in niso primerni za presaditev kostnega mozga.
It is not intended to provide practical advice on how to use Imatinib Teva. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
• chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control. 
• kronične mieloidne levkemije (KML), raka belih krvnih celic, pri katerem začnejo granulociti (vrsta belih krvnih celic) nenormalno rasti.
Imatinib Teva contains the active substance imatinib. 
Zdravilo Imatinib Teva vsebuje zdravilno učinkovino imatinib.
How has Imatinib Teva been studied? 
Kako je bilo zdravilo Imatinib Teva raziskano?
How is Imatinib Teva used? 
Kako se zdravilo Imatinib Teva uporablja?
How does Imatinib Teva work? 
Kako zdravilo Imatinib Teva deluje?
EU - Number Invented name 
EU - številka Izmišljeno ime Jakost
This summary was last updated in 09-2012. 
Povzetek je bil nazadnje posodobljen 09-2012.
This prevents the cells from dividing. 
To celicam preprečuje, da bi se delile.
It is available as an oral suspension. 
Na voljo je v obliki peroralne suspenzije.
The European Commission granted a marketing authorisation valid throughout the European Union for Xaluprine on 9 March 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Xaluprine, veljavno po vsej Evropski uniji, odobrila dne 9. marca 2012.
The CHMP also noted that the risks of using the medicine are well known. 
Ugotovil je tudi, da so tveganja pri uporabi zdravila dobro znana.
Treatment with this medicine should be supervised by a healthcare professional experienced in treating patients with ALL. 
Zdravljenje s tem zdravilom mora nadzorovati zdravstveni delavec, ki ima izkušnje z zdravljenjem bolnikov z ALL.
The dose is determined for each patient mainly by body surface area and may be adjusted according to its effects in the blood. 
Odmerek se določi za vsakega bolnika posebej, v glavnem na podlagi telesne površine, in se lahko prilagaja glede na njegove učinke v krvi.
The effectiveness of 6-mercaptopurine in slowing down the progression of ALL is already well known since it has been used for many years. 
Učinkovitost 6-merkaptopurina pri upočasnitvi napredovanja ALL je že znana, saj se uporablja že vrsto let.
It must also not be used at the same time as patients are having a yellow fever vaccination. 
Prav tako ga bolniki ne smejo uporabljati sočasno s cepljenjem proti rumeni mrzlici.
The medicine is taken by mouth, using the syringe provided in the pack, once per day in the evening. 
Zdravilo se jemlje peroralno s pomočjo brizge, ki je priložena v pakiranju, enkrat na dan, zvečer.
EPAR summary for the public mercaptopurine 
Povzetek EPAR za javnost merkaptopurin
This is a summary of the European public assessment report (EPAR) for Xaluprine. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xaluprine.
The Committee considered that an oral suspension allows more accurate dosing and is more convenient for children unable to swallow tablets. 
Odbor je menil, da peroralna suspenzija omogoča točnejše odmerjanje in je primernejša za otroke, ki niso zmožni pogoltniti tablet.
Because 6-mercaptopurine has been used for the treatment of ALL in the European Union for a number of years in the tablet form, the company presented results from the scientific literature of studies previously carried out with mercaptopurine tablets. 
Ker se 6-merkaptopurin v obliki tablet v Evropski uniji že vrsto let uporablja za zdravljenje ALL, je družba predstavila rezultate iz znanstvene literature, povezane s študijami, ki so jih izvedli s tabletam merkaptopurina.
The CHMP noted that mercaptopurine is established as an important treatment for ALL and that the only authorised form in the EU is a 50 mg tablet, making it difficult to adjust the dose for smaller children. 
CHMP je ugotovil, da je merkaptopurin uveljavljen kot pomembno zdravilo za zdravljenje ALL in da je njegova edina odobrena oblika v EU 50 mg tableta, kar otežuje prilagajanje odmerka za manjše otroke.
It can be taken with food (except dairy products) or on an empty stomach but this should be consistent from day to day. 
Zdravilo se lahko jemlje s hrano (razen mlečnih izdelkov) ali na tešče, vendar se morajo bolniki dosledno držati načina, ki si ga izberejo.
The Committee concluded that the benefits of Xaluprine are greater than its risks and recommended that it be granted marketing authorisation. 
Odbor je zaključil, da so koristi zdravila Xaluprine večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Because the number of patients with ALL is low, the disease is considered ‘rare', and Xaluprine was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 April 2009. 
Ker je bolnikov z ALL malo, velja ta bolezen za redko, zato je bilo zdravilo Xaluprine dne 30. aprila 2009 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
For more information, see the summary of product characteristics (also part of the EPAR). 
Več informacij najdete v povzetku glavnih značilnosti zdravila (ki je prav tako sestavni del EPAR).
6mercaptopurine prevents them from dividing and they eventually die, thereby slowing down the progression of the leukaemia. 
6-merkaptopurin limfocitom prepreči delitev, zato ti sčasoma odmrejo, kar upočasni napredovanje levkemije.
The summary of the opinion of the Committee for Orphan Medicinal Products for Xaluprine can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations. 
Povzetek mnenja Odbora za zdravila sirote za zdravilo Xaluprine je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
In the body, 6-mercaptopurine is converted within cells into a substance that interferes with the production of new DNA. 
V telesu se 6-merkaptopurin znotraj celic pretvori v učinkovino, ki ovira nastanek nove DNK.
For more information about treatment with Xaluprine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Xaluprine preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Xaluprine is a medicine that contains the active substance mercaptopurine. 
Xaluprine je zdravilo, ki vsebuje zdravilno učinkovino merkaptopurin.
The active substance in this medicine, mercaptopurine has a similar chemical structure to purine, which is one of the fundamental chemicals that make up DNA. 
Zdravilna učinkovina v tem zdravilu, merkaptopurin, ima podobno kemijsko zgradbo kot purin, ki je ena od osnovnih spojin, ki tvorijo DNK.
The bioavailability study showed that Xaluprine is comparable to the tablets, but it works in a more predictable way and has a higher rate of absorption, for which reason the dose will need to be adjusted when a patient switches from one formulation to the other. 
Študija biološke uporabnosti je pokazala, da je zdravilo Xaluprine primerljivo s tabletami, vendar je njegovo delovanje bolj predvidljivo in ima višjo stopnjo absorpcije, zato je treba odmerek prilagoditi, kadar bolnik eno obliko zdravila zamenja z drugo.
Medicines containing mercaptopurine in tablet form have been already used in the EU for many years to treat patients with ALL. 
Zdravila, ki vsebujejo merkaptopurin, se v obliki tablet za zdravljenje bolnikov z ALL v EU uporabljajo že vrsto let.
Xaluprine must not be used in people who are hypersensitive (allergic) to mercaptopurine or any of the other ingredients. 
Zdravila Xaluprine ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) merkaptopurin ali katero koli drugo sestavino zdravila.
Xaluprine is used to treat children, adolescents and adults who have acute lymphoblastic leukaemia (ALL), a cancer of the lymphocytes (a type of white blood cell). 
Zdravilo Xaluprine se uporablja za zdravljenje otrok, mladostnikov in odraslih, ki imajo akutno limfoblastno levkemijo (ALL), tj. raka limfocitov (vrste belih krvnih celic).
What benefit has Xaluprine shown during the studies? 
Kakšne koristi je zdravilo Xaluprine izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Xaluprine, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
A study was also carried out to compare the bioavailability of Xaluprine, which is an oral suspension, with that of the tablet. 
Izvedena je bila tudi študija, kjer so primerjali biološko uporabnost zdravila Xaluprine, ki je peroralna suspenzija, z biološko uporabnostjo tablete.
The most common side effects with mercaptopurine (seen in more than 1 patient in 10) are leucopenia (low white blood cell counts) and thrombocytopenia (low blood platelet counts). 
Najpogostejši neželeni učinki merkaptopurina (opaženi pri več kot 1 bolniku od 10) so levkopenija (zmanjšano število belih krvnih celic) in trombocitopenija (zmanjšano število trombocitov).
The full EPAR for Xaluprine can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Xaluprine je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The bioavailability study compared the way the two different forms of the same medicine are absorbed in the human body and the levels of the active substance they produce. 
V študiji biološke uporabnosti so primerjali, kako človeško telo absorbira različni obliki istega zdravila, in koncentraciji zdravilne učinkovine, ki ju ti obliki dosežeta.
The added benefit of Xaluprine is that, as an oral suspension, it will provide more accuracy in dosing and it is easier to be taken by children. 
Dodatna prednost zdravila Xaluprine je to, da ga bo možno kot peroralno suspenzijo točneje odmeriti in da ga bodo otroci lažje jemali.
Other information about Xaluprine 
Druge informacije o zdravilu Xaluprine:
In ALL the lymphocytes multiply too quickly and live for too long. 
Pri bolnikih z ALL se limfociti delijo prehitro in propadajo prepočasi.
What is the risk associated with Xaluprine? 
Kakšna tveganja so povezana z zdravilom Xaluprine?
Why has Xaluprine been approved? 
Zakaj je bilo zdravilo Xaluprine odobreno?
What is Xaluprine used for? 
Za kaj se zdravilo Xaluprine uporablja?
How does Xaluprine work? 
Kako zdravilo Xaluprine deluje?
How has Xaluprine been studied? 
Kako je bilo zdravilo Xaluprine raziskano?
How is Xaluprine used? 
Kako se zdravilo Xaluprine uporablja?
What is Xaluprine? 
Kaj je zdravilo Xaluprine?
Date of first authorisation: 27 May 2015 Date of latest renewal: 
Datum prve odobritve: 27. maj 2015 Datum zadnjega podaljšanja:
• feeling tired. 
• občutek utrujenosti.
Therefore, use in these patients should be avoided. 
Zato se je treba uporabi zdravila pri teh bolnikih izogibati.
Safety and efficacy were maintained throughout all cycles. 
Varnost in učinkovitost sta se ohranili skozi celoten čas študije.
Dialysis studies have not been performed. 
Študije dialize niso bile opravljene.
In case of overdose, the medicinal product should be discontinued and general supportive treatment and monitoring should be provided. 
V primeru prevelikega odmerjanja je treba zdravljenje z zdravilom ukiniti ter poskrbeti za splošno podporno zdravljenje in spremljanje.
Delayed phase 
Zakasnjena faza
Women of childbearing potential/ contraception in females 
Ženske v rodni dobi/kontracepcija pri ženskah
• rifampicin - to treat tuberculosis (TB) and other infections. 
• rifampicin za zdravljenje tuberkuloze (TB) in drugih okužb.
These effects were not considered clinically important. 
Teh učinkov niso ocenili kot klinično pomembne.
* p-value from Cochran-Mantel-Haenszel test, stratified by age class and region. 
*Vrednost p iz Cochran-Mantel-Haenszelovega testa, statificirana po starostni kategoriji in regiji.
Akynzeo contains two medicines (‘active substances') called: 
Zdravilo Akynzeo vsebuje dve zdravili (»učinkovini«), imenovani:
Elimination via both routes was estimated to be complete by Day 29-30 post-dose. 
Ocenili so, da je izločanje prek obeh poti dokončano 29. do 30. dan po odmerjanju.
The effects were reversible or partially reversible after the recovery period. 
Po obdobju okrevanja so bili učinki reverzibilni ali delno reverzibilni.
A total of 724 patients (99.9%) were treated with cyclophosphamide. 
Skupno 724 bolnikov (99,9 %) je bilo zdravljenih s ciklofosfamidom.
There have also been reports of serotonin syndrome. 
Poročali so tudi o serotoninskem sindromu.
The hard capsule should be swallowed whole. 
Trdo kapsulo je treba pogoltniti celo.